What is it used for?
JAYPIRCA® is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor. This indication is approved under accelerated approval based on response rate . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. JAYPIRCA is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor.JAYPIRCA® is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor. This indication is approved under accelerated approval based on response rate . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. JAYPIRCA is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor.
Read the primary sourceThis source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Product details
- Active ingredient
- pirtobrutinibpirtobrutinib
- Form and strength
- TABLET, COATED · 50 mg; TABLET, COATED · 100 mgTABLET, COATED · 50 mg; TABLET, COATED · 100 mg
- Manufacturer / applicant
- ELI LILLY AND COMPANYELI LILLY AND COMPANY
Tablets: Each 50 mg tablet is blue, arc-triangle shaped, film-coated, and debossed with “Lilly 50” on one side and “6902” on the other side. Each 100 mg tablet is blue, round, film-coated, and debossed with “Lilly 100” on …Tablets: Each 50 mg tablet is blue, arc-triangle shaped, film-coated, and debossed with “Lilly 50” on one side and “6902” on the other side. Each 100 mg tablet is blue, round, film-coated, and debossed with “Lilly 100” on …
Safety and clinical review
- InfectionsInfections
- HemorrhageHemorrhage
- CytopeniasCytopenias
- Cardiac ArrhythmiasCardiac Arrhythmias
- Second Primary MalignanciesSecond Primary Malignancies
- Hepatotoxicity, Including Drug-Induced Liver InjuryHepatotoxicity, Including Drug-Induced Liver Injury
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Read the primary sourcePrepare your enquiry
Include the brand or generic name, strength, dosage form, requested quantity and country where care is needed. You can attach a prescription when you continue.
Questions patients ask
What is Jaypirca used for?
JAYPIRCA® is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor. This indication is approved under accelerated approval based on response rate . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. JAYPIRCA is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor.JAYPIRCA® is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor. This indication is approved under accelerated approval based on response rate . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. JAYPIRCA is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor.
This source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Which formulation of Jaypirca should I ask about?
TABLET, COATED · 50 mg; TABLET, COATED · 100 mgTABLET, COATED · 50 mg; TABLET, COATED · 100 mg
Read the primary sourceWhat determines the price of Jaypirca?
A current quote depends on the exact presentation, quantity, provider and access arrangements. A catalogue entry is not a stock or delivery promise. Medical charges are paid to the provider, separately from coordination fees.
What should I check before using Jaypirca?
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Sources and review scope
FDA prescribing informationThis source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.